Install
In the final analysis of the phase III POTOMAC trial reported in The Lancet, De Santis et al found that the addition of durvalumab to bacillus Calmette-Guérin (BCG) induction and maintenance improved disease-free survival in patients with high-risk non–muscle-invasive bladder cancer (NMIBC) who underwent transurethral
- 19articles · 30d
- 3+ day agolatest article
- Aug 18, 2026earliest in window
- 21%with images
- 333avg words
articles per day
Covers
People
Places
Organizations
Categories
- Medical 19
- Health & Wellness 19
- Health 16
- Science & Technology 2
- Human Interest 1
Site tags
Bylines
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
Hold with a pointer, or hold Space or Enter.
News
Web
External web results are waiting for the human check. Complete the press-and-hold control above. Google advertising and AI choices remain separate after verification.